4th Annual CNPN Symposium
INVITED SPEAKERS
Ruedi Aebersold, ETH Zurich.
He is one of the world’s leaders in MS-based proteomics, and the recipient of numerous international awards for his innovatives contributions in this field. Well known for his development of isotope coded affinity tag (ICAT) reagents, Dr. Aebersold continues to implement new approaches for quantification, both for global profiling of proteomes and for in-depth functional proteomics to characterize cell signaling regulation in health and disease.
Gary Bader, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto.
He is a world leader in the development of open-source biological pathway, network databases, visualization and analysis software for protein-protein interactions. He studies the organization and evolution of biological systems using computational biology and bioinformatics techniques to predict specific molecular interactions including mutations that cause disease.
Daniel Chan, Johns Hopkins University.
His research is focused on proteomic biomarker discovery, validation and translation using MS and affinity capture methods, such as protein and lectin microarrays and immunoassays. Clinical applications include early detection, prognosis and monitoring therapies for ovarian, prostate, breast and colon cancers.
Eleftherios Diamandis, University of Toronto.
His research interests are centered on the discovery and validation of novel cancer biomarkers, proteomics, translational research and the role of kallikrein enzymes in health and disease; basic and translational aspects of tumor metastasis. A focus of his work is on the role of quantitative proteomics in pancreatic cancer biomarker discovery and validation.
Bruno Domon, Luxembourg Clinical Proteomics Center.
He heads the laboratory for clinical proteomics at the CRP Sante, in Luxembourg. He is interested in the development of quantitative proteomics and has been pioneering targeted methods leveraging novel mass spectrometry techniques. He is developing and applying these techniques for routine clinical applications.
Andrew Emili, University of Toronto.
Dr. Emili’s lab is interested in comprehensive analysis of proteins expressed by the genome of eukaryotic cells using comprehensive, and complementary proteomics methods. His research aims are to understand the function and integration of the complex biochemical circuitry that underlies cell growth and proliferation.
Albert Heck, University of Utrecht.
Dr. Heck`s group develops and implements innovative MS methods for efficient and detailed characterization of protein and other biomolecules in relation to their biological function. The emphasis is on the structural characterization of proteins, their post-translational modifications, and the investigation of protein complexes important in e.g. protein folding, protein ligand binding, and the formation of tertiary and quaternary structures.
Lynn Megeny, Ottawa Hospital Research Institute.
His group is interested in defining the organizing principles and biologic impact of signal transduction pathways in stem cell differentiation and cell fate. He has used proteomic analyses to characterize the regulatory pathways in myogenesis and embryonic stem cell differentiation.
Akhilesh Pandey, Johns Hopkins University.
Dr. Pandey’s lab uses Systems Biology approaches that combines molecular biology, analytical chemistry and computational biology with various "Omics" technologies including genomics and proteomics to understand signaling pathways and to identify therapeutic targets and biomarkers in a number of cancers.
Peipei Ping, University of California at Los Angeles.
Her research program focuses on the dynamic alterations of proteome biology in cardiovascular medicine. She is interesting on how altered molecular pathways or organelle proteomes contribute to the pathogenesis of myocardial ischemic injury and how regulatory mechanisms activate cardioprotection to minimize injury.
Juri Rappsilber, University of Edinburgh.
Dr. Rappsilber’s research activities aim at developing and applying novel methods to study the conformation and interaction dynamics of proteins in complex mixtures (3D proteomics), and chromatin-associated processes (e.g. RNA polymerase II in complex with transcription factor IIF) in health and disease.
Igor Stagljar, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto.
His research activities are focused on interaction proteomics and the maintenance of genome stability. He is internationally known for the development of the split-ubiquitin membrane yeast two-hybrid technology. Molecular, cellular, chemical genomic and proteomic approaches are used to study the function of yeast and human membrane proteins, and bacterial proteins involved in pathogenicity.
Gerold Schmitt-Ulms, University of Toronto.
His work contributes to two strands of research at the interface of proteomics and neurodegenerative disease research: the development of strategies for the study of protein interactions and the application of these strategies to dissect the early etiology of Alzheimer's disease and prion diseases.
Mike Tyers, Université de Montréal.
Research in Dr. Tyers’s group uses biochemical, small molecule, genetic approaches, high content microscopy, mass spectrometry and computational methods to understand fundamental cell processes conserved through the kingdom of all self sustaining life forms. In particular they focus on the cell cycle machinery as a crucial target of the many signaling pathways that coordinate growth and development.
David Wishart, University of Alberta.
His research interests are focused on structural biology and on the development of computational tools to facilitate the determination of protein structures using NMR and protein cross-linking with MS. He has active research programs in bioinformatics, prion biology, synthetic biology, nanotechnology and metabolomics.
Jeffrey Wrana, Samuel Lunenfeld Research Institute, Toronto.
He is the recipient of multiple National awards for his transformative research on cancer. He uses high-throughput proteomics and genetic tools, to understand how morphogen cell signaling pathways and the higher organizational structure controls cell behavior in development and cancer.